Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics — Paul G. Richardson (2021) | RDL Network
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Article 2021 en
Authors
PR
Paul G. Richardson
FS
Fredrik Schjesvold
KW
Katja Weisel
Abstract
1 min read
These findings confirmed the benefits of PVd at first relapse, including in patients with poor prognostic factors.
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul G. Richardson
Fredrik Schjesvold, Meletios A Dimopoulos, Meral Beksaç, Albert Oriol, Jindriska Lindsay, Anna Marina Liberati, Mónica Galli, Paweł Robak, Katja Weisel, Alessandra Larocca, Münci Yağcı, Filiz Vural, Larry Anderson, Abraham S. Kanate, Eva Casal Mendez, Ruiyun Jiang, Shankar Srinivasan, Lara Grote, Tsvetan Biyukov, Paul G. Richardson
Albert Oriol Rocafiguera, Meletios A Dimopoulos, Fredrik Schjesvold, Meral Beksaç, Münci Yağcı, Alessandra Larocca, Shien Guo, Yutian Mu, Kevin Hong, Sujith Dhanasiri, Paul G. Richardson, Katja Weisel
Albert Oriol, Meletios A Dimopoulos, Fredrik Schjesvold, M. Beksac, Münci Yağcı, Alessandra Larocca, S. Guo, Y. Mu, Kevin Hong, Sujith Dhanasiri, PG Richardson, Katja Weisel
Albert Oriol, Meletios A Dimopoulos, Fredrik Schjesvold, Meral Beksaç, Thierry Façon, Sujith Dhanasiri, Shien Guo, Yutian Mu, Kevin Hong, Christian Gentili, Mónica Galli, Münci Yağcı, Alessandra Larocca, Paul G. Richardson, Katja Weisel
Discussion(0)
No comments yet. Be the first to comment.